Castle Biosciences, Inc. CSTL

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on DecisionDx-Melanoma at the European Academy of Dermatology and Venereology (EADV) Congress 2026, taking place Sept. 30–Oct. 3 in Vienna, Austria.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study showing that its TissueCypher® Barrett's Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett's esophagus (NDBE). In the study, clinicians changed their management recommendations 90% of the time after receiving TissueCypher results, including escalating management for all patients with i

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and strong patient interest in molecular testing to help guide systemic therapy selection. The findings support the clinical need for molecular guidance in AD care. Castle's AdvanceAD-Tx test is designed to address this need

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the opening of its new laboratory and office facility in Scottsdale, Arizona. The Company will commemorate the milestone with a grand opening celebration at the new facility, located at 8667 E. Hartford Drive, on Tuesday, October 6, 2026, at 3:30 p.m. Mountain Standard Time.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new decision modeling study showing that the TissueCypher® Barrett's Esophagus test (TSP-9) can help better align Barrett's esophagus (BE) management with a patient's individual risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). In the study, simulated use of TissueCypher significantly increased appropriate m

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a multi-center study in the Journal of the American Academy of Dermatology (JAAD) validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC).1

Shares of Castle Biosciences (CSTL) have recently risen about 37%, following increasing agreement among Wall Street analysts on earnings estimate revisions that point to a more constructive view of the company’s earnings outlook. At around $34.11 per share, Castle Biosciences has seen strong recent momentum, with a 30 day share price return of about 39.6% and a 90 day share price return of about 54.3%. The 1 year total shareholder return of about 53.1% suggests that recent optimism around...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m. Eastern time.

Moby summary of Castle Biosciences, Inc.'s Q2 2026 earnings call

Castle Biosciences raises 2026 revenue outlook to $365-$375M as TissueCypher volumes jump 63% and AdvanceAD-Tx secures favorable Medicare pricing.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter ended June 30, 2026.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time.